{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:11:28Z","timestamp":1791497488547,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.msard.2024.105683","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:19:13Z","timestamp":1715473153000},"page":"105683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of comorbidities on relapsing rates of Neuromyelitis Optica Spectrum Disorders: Insights from a longitudinal study in Taiwan"],"prefix":"10.1016","volume":"87","author":[{"given":"Jung Lung","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen Jen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Feng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chou","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Che","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hsuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyi-Huey","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sun","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105683_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2017.10.030","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder: a case report and review of the literature","volume":"48","author":"Annus","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2024.105683_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.msard.2018.12.010","article-title":"Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment","volume":"28","author":"Banerjee","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105683_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102685","article-title":"Frequency of comorbidities in Neuromyelitis Optica spectrum disorder","volume":"48","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.105683_bib0004","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s10072-023-06611-4","article-title":"Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases","volume":"44","author":"Carnero Contentti","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2024.105683_bib0005","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-023-06611-4","article-title":"Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases","author":"Carnero Contentti","year":"2023","journal-title":"Neurol. Sci"},{"issue":"11","key":"10.1016\/j.msard.2024.105683_bib0006","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1111\/ene.15479","article-title":"Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach","volume":"29","author":"Dinoto","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105683_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660230","article-title":"Early initiation of tocilizumab treatment against moderate-to-severe myelitis in neuromyelitis optica spectrum disorder","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.105683_bib0008","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2024.105683_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102425","article-title":"Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015","volume":"45","author":"Fang","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.msard.2024.105683_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaneurol.2013.6331","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4","volume":"71","author":"Figueroa","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105683_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.msard.2019.04.023","article-title":"Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma","volume":"32","author":"Gao","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105683_bib0012","article-title":"Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort","author":"Gholizadeh","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105683_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104023","article-title":"The description of neuromyelitis optica spectrum disorder: patient registry in Yangtze River Delta area of China","volume":"66","author":"Huang","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2024.105683_bib0014","first-page":"827","article-title":"[Clinical features and prognostic analysis of neuromyelitisoptica spectrum disease with sjogrensyndrome]","volume":"97","author":"Jia","year":"2017","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.msard.2024.105683_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103494","article-title":"Clinical significance of anti-SSA\/Ro antibody in Neuromyelitis optica spectrum disorders","volume":"58","author":"Lin","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105683_bib0016","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00415-019-09647-9","article-title":"Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan","volume":"267","author":"Lin","year":"2020","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2024.105683_bib0017","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jfma.2021.11.002","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","volume":"121","author":"Liu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.msard.2024.105683_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105683_bib0019","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1212\/NXI.0000000000000188","article-title":"Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder","volume":"3","author":"Nosadini","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2024.105683_bib0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/00207454.2013.854208","article-title":"Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?","volume":"124","author":"Ontaneda","year":"2014","journal-title":"Int. J. Neurosci."},{"issue":"5","key":"10.1016\/j.msard.2024.105683_bib0021","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2024.105683_bib0022","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"issue":"13","key":"10.1016\/j.msard.2024.105683_bib0023","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458517731914","article-title":"Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies","volume":"24","author":"Sepulveda","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105683_bib0024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.105683_bib0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang gung research database: a multi-institutional database consisting of original medical records","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed. J."},{"issue":"4","key":"10.1016\/j.msard.2024.105683_bib0026","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5414\/NP300855","article-title":"Anti-aquaporin 4 related paraneoplastic neuromyelitis optica in the presence of adenocarcinoma of the lung","volume":"34","author":"Verschuur","year":"2015","journal-title":"Clin. Neuropathol."},{"issue":"2","key":"10.1016\/j.msard.2024.105683_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000322740","article-title":"The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan","volume":"65","author":"Wang","year":"2011","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105683_bib0028","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2024.105683_bib0029","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2024.105683_bib0030","first-page":"159","article-title":"Clinical features of neuromyelitis optica spectrum disorders with connective tissue diseases","volume":"43","author":"Xie","year":"2021","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.msard.2024.105683_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2415-14-106","article-title":"Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma","volume":"14","author":"Yang","year":"2014","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.msard.2024.105683_bib0032","article-title":"Relatively early and late-onset neuromyelitis optica spectrum disorder in central China","volume":"13","author":"Yu","year":"2022","journal-title":"Clinical Characteristics and Prognostic Features. Front Neurol"},{"key":"10.1016\/j.msard.2024.105683_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103786","article-title":"Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus","volume":"62","author":"Zhang","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2024.105683_bib0034","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10072-016-2751-2","article-title":"Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjogren's syndrome","volume":"38","author":"Zhong","year":"2017","journal-title":"Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T12:07:22Z","timestamp":1720872442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"alternative-id":["S2211034824002608"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105683","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of comorbidities on relapsing rates of Neuromyelitis Optica Spectrum Disorders: Insights from a longitudinal study in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105683"}}